Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

Related Articles by Review for PubMed (Select 23620441)

1.

Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.

Bock ME, Price HE, Gallon L, Langman CB.

Clin J Am Soc Nephrol. 2013 Aug;8(8):1304-11. doi: 10.2215/CJN.07680712. Epub 2013 Apr 25.

2.

Serum suPAR in patients with FSGS: trash or treasure?

Maas RJ, Deegens JK, Wetzels JF.

Pediatr Nephrol. 2013 Jul;28(7):1041-8. doi: 10.1007/s00467-013-2452-5. Epub 2013 Mar 21. Review.

PMID:
23515666
3.

Soluble urokinase receptor and focal segmental glomerulosclerosis.

Reiser J, Wei C, Tumlin J.

Curr Opin Nephrol Hypertens. 2012 Jul;21(4):428-32. doi: 10.1097/MNH.0b013e328354a681. Review.

PMID:
22569341
4.

Permeability factors in focal and segmental glomerulosclerosis.

Reiser J, Nast CC, Alachkar N.

Adv Chronic Kidney Dis. 2014 Sep;21(5):417-21. doi: 10.1053/j.ackd.2014.05.010. Review.

PMID:
25168830
5.

Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.

McCarthy ET, Sharma M, Savin VJ.

Clin J Am Soc Nephrol. 2010 Nov;5(11):2115-21. doi: 10.2215/CJN.03800609. Epub 2010 Oct 21. Review.

6.

Clinical picture and outcome of primary focal segmental glomerulosclerosis.

Korbet SM.

Nephrol Dial Transplant. 1999;14 Suppl 3:68-73. Review.

7.

Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future.

Maas RJ, Deegens JK, Wetzels JF.

Nephrol Dial Transplant. 2014 Dec;29(12):2207-16. doi: 10.1093/ndt/gfu355. Review.

PMID:
25416821
8.

Novel therapies for FSGS: preclinical and clinical studies.

Malaga-Dieguez L, Bouhassira D, Gipson D, Trachtman H.

Adv Chronic Kidney Dis. 2015 Mar;22(2):e1-6. doi: 10.1053/j.ackd.2014.10.001. Review.

PMID:
25704355
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk